Literature DB >> 8878593

Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process.

L Rabbaa1, S Dautrey, N Colas-Linhart, C Carbon, R Farinotti.   

Abstract

The aim of this work was to examine the mechanism involved in intestinal elimination of the two optical isomers of ofloxacin in the rat. An intestinal segment was isolated in situ and perfused with saline, while drug solution was administered via the carotid artery. Blood samples and intestinal effluents were collected and analyzed by a high-performance liquid chromatography method. We observed saturable and stereoselective intestinal elimination of the ofloxacin enantiomers. The elimination process favored the R-(+) form of the molecule. After a parenteral dose of 20 mg of racemic ofloxacin per kg of body weight, intestinal clearances were 0.23 +/- 0.03 versus 0.30 +/- 0.03 ml/min for S-(-)- and R-(+)-ofloxacin, respectively. Ciprofloxacin and pefloxacin interfered with ofloxacin elimination and significantly reduced the intestinal clearance of S-(-)- and R-(+)-ofloxacin. With concomitant ciprofloxacin, intestinal clearances became 0.13 +/- 0.02 versus 0.17 +/- 0.03 ml/min and 0.14 +/- 0.01 versus 0.19 +/- 0.05 ml/min with pefloxacin for S-(-)- and R-(+)-ofloxacin, respectively. Those findings argue for the presence of a common transport system in the rat intestine with variable affinities for fluoroquinolones. In addition, verapamil and quinidine, two P-glycoprotein blockers, significantly reduced the intestinal elimination of both ofloxacin isomers (with concomitant verapamil, intestinal clearances were 0.12 +/- 0.02 versus 0.18 +/- 0.03 ml/min for S-(-)- and R-(+)-ofloxacin, respectively, while with concomitant quinidine, values were 0.18 +/- 0.01 versus 0.23 +/- 0.01 ml/min without modifying their areas under the concentration-time curve in serum. Similar results were found with another fluoroquinolone, ciprofloxacin, in previous work. P-glycoprotein appears to be involved in the intestinal elimination of fluoroquinolones in rats. The characterization of fluoroquinolone intestinal elimination has significant clinical relevance for the better evaluation of the influence of this secretory pathway on antibiotic efficacy and selection of resistant bacteria within the intestinal flora.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878593      PMCID: PMC163485     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Absorption of drugs from the rat small intestine.

Authors:  L S SCHANKER; D J TOCCO; B B BRODIE; C A HOGBEN
Journal:  J Pharmacol Exp Ther       Date:  1958-05       Impact factor: 4.030

2.  Clinical uses of nalidixic acid analogues: the fluoroquinolones.

Authors:  N Høiby
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

3.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

Authors:  F Thiebaut; T Tsuruo; H Hamada; M M Gottesman; I Pastan; M C Willingham
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

4.  Pharmacokinetics of ofloxacin after parenteral and oral administration.

Authors:  H Lode; G Höffken; P Olschewski; B Sievers; A Kirch; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

5.  Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli.

Authors:  K Hirai; H Aoyama; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

6.  The quinolones.

Authors:  R J Fass
Journal:  Ann Intern Med       Date:  1985-03       Impact factor: 25.391

7.  Comparative effects of verapamil, tiapamil, diltiazem and nifedipine on systemic and splanchnic hemodynamics in man.

Authors:  S Gasic; H G Eichler; A Korn
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1987-09

8.  Optimal perfusion rate determined for in situ intestinal absorption studies in rats.

Authors:  P M Savina; A E Staubus; T S Gaginella; D F Smith
Journal:  J Pharm Sci       Date:  1981-03       Impact factor: 3.534

9.  The mechanism of binding of dihydropyridine calcium channel blockers to rat brain membranes.

Authors:  G A Weiland; R E Oswald
Journal:  J Biol Chem       Date:  1985-07-15       Impact factor: 5.157

10.  (-)-S-[3H]CGP-12177 and its use to determine the rate constants of unlabeled beta-adrenergic antagonists.

Authors:  H Affolter; C Hertel; K Jaeggi; M Portenier; M Staehelin
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

View more
  6 in total

1.  Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates.

Authors:  S Dautrey; K Felice; A Petiet; B Lacour; C Carbon; R Farinotti
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters.

Authors:  J A Schrickx; J Fink-Gremmels
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

3.  Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model.

Authors:  Elise D Pieterman; Lindsey H M Te Brake; Gerjo J de Knegt; Aart van der Meijden; Jan-Willem C Alffenaar; Hannelore I Bax; Rob E Aarnoutse; Jurriaan E M de Steenwinkel
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes.

Authors:  C Gokbulut; V Y Cirak; B Senlik
Journal:  Vet Res Commun       Date:  2006-10       Impact factor: 2.459

5.  Mechanism underlying levofloxacin uptake by human polymorphonuclear neutrophils.

Authors:  D Vazifeh; A Bryskier; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

6.  Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors.

Authors:  E Cormet-Boyaka; J F Huneau; A Mordrelle; P N Boyaka; C Carbon; E Rubinstein; D Tomé
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.